Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13685884 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TSHRCYP2D6CYP2C19HIF1A | |
| Methylpiperazine SCHEMBL9795539 | 0.81 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL10157896 | 0.81 | ALDH1A1 (0.48) | ALDH1A1BCHEACHE | |
| Silver SCHEMBL2232380 | 0.81 | ALDH1A1 (0.48) | ALDH1A1BCHEACHE | |
| SCHEMBL4737789 | 0.81 | ALDH1A1 (0.48) | ALDH1A1BCHEACHE | |
| SCHEMBL2010219 | 0.81 | ALDH1A1 (0.48) | ALDH1A1BCHEACHE | |
| SCHEMBL2015296 | 0.79 | ALDH1A1 (0.46) | ALDH1A1BCHEACHECYP2C19 | |
| SCHEMBL9795445 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL14163142 | 0.78 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL3862398 | 0.77 | ALDH1A1 (0.54) | ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111548482-B | Nitric oxide donor modified copolymer, sustained-release preparation containing nitric oxide donor modified copolymer, and preparation method and application of nitric oxide donor modified copolymer | 复旦大学 | 2022-09-13 | — | — | CN | claimed |
| CN-111548482-A | Nitric oxide donor modified copolymer, sustained-release preparation containing nitric oxide donor modified copolymer, and preparation method and application of nitric oxide donor modified copolymer | 复旦大学 | 2020-08-18 | — | — | CN | claimed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025091177-A1 | FPR1 MODULATORS, COMPOSITIONS COMPRISING THE MODULATOR, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2025-05-08 | — | — | WO | disclosed |
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-06-08 | — | — | US | disclosed |
| EP-4175943-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | Biofront Therapeutics (Beijing) Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023005180-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2023-02-02 | — | — | WO | disclosed |
| CN-111548482-B | Nitric oxide donor modified copolymer, sustained-release preparation containing nitric oxide donor modified copolymer, and preparation method and application of nitric oxide donor modified copolymer | 复旦大学 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022022669-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2022-02-03 | — | — | WO | disclosed |
| CN-113767104-A | Bifunctional compounds and methods of use thereof | 百放英库医药科技(北京)有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-1673384-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1497268-A4 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1497268-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-5037849-A | For treatment of heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1991-08-06 | — | — | US | disclosed |
| EP-0366004-A1 | Cyclic azaaliphatic compounds with a nitroxy group, process for their preparation and pharmaceutical compositions thereof | Roche Diagnostics GmbH (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | TBXA2R, TXNRD3, NOS3 | ALDH1A1 339/4885CYP2C9 1457/4885BCHE 4703/4885 |
| US-20230174482-A1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | PDE1A, PDE3B, PDE1B | ALDH1A1 471/4885CYP2C9 980/4885BCHE 113/4885 |
| US-11987556-B2 | Dual-functional compounds and methods of use | PDE1A, PDE3B, PDE1B | ALDH1A1 471/4885CYP2C9 980/4885BCHE 113/4885 |
| US-20030203915-A1 | Nitric oxide donors, compositions and methods of use related applications | NOS1, NOS2, NOS3 | ALDH1A1 507/4885CYP2C9 439/4885BCHE 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.